Aerovate Therapeutics, Inc.

NASDAQ (USD): Aerovate Therapeutics, Inc. (AVTE)

Last Price

1.66

Today's Change

-0.01 (0.59%)

Day's Change

1.52 - 1.73

Trading Volume

2,434,914

Profile
AVTE

Exchange:  NASDAQ Global Market NASDAQ Global Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. Timothy P. Noyes M.B.A. Mr. Timothy P. Noyes M.B.A.

Full Time Employees:  51 51

IPO Date:  2021-06-30 2021-06-30

CIK:  0001798749 0001798749

ISIN:  US0080641071 US0080641071

CUSIP:  008064107 008064107

Beta:  1.30 1.30

Last Dividend:  0.00 0.00

Dcf Diff:  0.79 0.79

Dcf:  0.87 0.87

Description

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Address

930 Winter Street,
Waltham, MA 02116, US

617 443 2400

http://aerovatetx.com

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment